A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
- Registration Number
- NCT00545688
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This 4 arm study will evaluate the efficacy and safety of 4 neoadjuvant treatment regimens in female patients with locally advanced, inflammatory or early stage HER2 positive breast cancer. Before surgery, patients will be randomized to one of 4 treatment arms, to receive 4 cycles of a)Herceptin + docetaxel b)Herceptin + docetaxel + pertuzumab c)Herceptin + pertuzumab or 4)pertuzumab + docetaxel. Pertuzumab will be administered at a loading dose of 840mg iv, then 420mg iv 3-weekly, Herceptin at a loading dose of 8mg/kg iv then 6mg/kg 3-weekly, and docetaxel at a dose of 75mg/m2 escalating to 100mg/m2 3-weekly. During the entire pre- and post-surgery period all patients will receive adequate chemotherapy as per standard of care, as well as any surgery and/or radiotherapy as required. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 417
- female patients, >=18 years of age;
- locally advanced, inflammatory or early stage invasive breast cancer;
- HER2 positive (HER2+++ by IHC or FISH/CISH+).
- metastatic disease (Stage IV) or bilateral breast cancer;
- previous anticancer therapy or radiotherapy for any malignancy;
- other malignancy, other than cancer in situ of the cervix, or basal cell cancer;
- insulin-dependent diabetes;
- clinically relevant cardiovascular disease.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Herceptin - 3 Herceptin - 1 Herceptin - 1 Docetaxel - 2 Docetaxel - 3 Pertuzumab - 2 Pertuzumab - 4 Docetaxel - 4 Pertuzumab -
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving pCR by Hormone Receptor Status Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4) pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants were classified as Estrogen and/or Progesterone positive (+ve), Estrogen and/or Progesterone negative (-ve) or receptor status unknown. Participants with invalid/missing pCR assessments were defined as non-responders.
Percentage of Participants Achieving pCR by Lymph Node Status Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4) pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Lymph node status was defined as either negative lymph node at surgery or positive lymph node at surgery. Participants with invalid/missing pCR assessments were defined as non-responders.
Percentage of Participants Achieving Pathological Complete Response (pCR) Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4) pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants with invalid/missing pCR assessments were defined as non-responders
Percentage of Participants Achieving pCR by Breast Cancer Type Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4) pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Based on the type of breast cancer participants were categorized as those with 1. Operable breast cancer, 2. Inflammatory breast cancer and 3. Locally advanced breast cancer. Participants with invalid/missing pCR assessments were defined as non-responders.
Percentage of Participants Achieving pCR by Presence or Absence of Residual Intraductal Carcinoma (DCIS) / Intalobular Carcinoma (LCIS) Approximately 4 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 4) pCR was defined as an absence of invasive neoplastic cells at microscopic examination of the tumor remnants after surgery following primary systemic therapy. Participants with invalid/missing pCR assessments were defined as non-responders.
- Secondary Outcome Measures
Name Time Method Percentage of Participants Achieving Best Primary Tumor Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Disease Progression [PD]) During Neo-Adjuvant Treatment by X-Ray/Mammography Baseline up to Cycle 4 (assessed at, Baseline and Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months Tumor assessments were made based upon the Response Evaluation Criteria in Solid Tumors (RECIST) criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for primary breast tumor using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is greater than (\>)0 at screening or cycle 1 Day 1; PR: if measurement is at least a 30 percent (%) decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline.
Percentage of Participants Achieving Best Overall Response (CR, PR, SD or PD) During Neo-Adjuvant Period by X-Ray/Mammography Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months Tumor assessments were made based on the RECIST criteria - version 1.0 The overall response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Percentage of Participants Achieving Best Primary Breast Tumor Response (CR, PR, SD or PD) During Neo-Adjuvant Period by Clinical Examination Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for primary breast tumor using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Percentage of Participants Achieving Best Overall Response (CR, PR, SD or PD) During the Neo-Adjuvant Period by Clinical Examination Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes); SD: if measurement at a given cycle is not sufficient shrinkage to qualify for neither PR nor sufficient increase to qualify for PD compared to baseline levels. PD: if lesion is at least a 20 % increase from measurements at baseline. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Percentage of Participants Achieving Clinical Response During Neo-Adjuvant Period by X-Ray/Mammography Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months Clinical response was determined based on tumor measurements by sponsor in combination with tumor response assessment by investigator. Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Percentage of Participants Achieving Clinical Response During Neo-Adjuvant Period by Clinical Examination Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months Tumor assessments were made based on the RECIST criteria - version 1.0 The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment. Primary breast tumor clinical response is based on primary breast tumor assessment. Overall response is derived based on the sum total of breast tumors and all nodes examined.
Time to Clinical Response During Neo-Adjuvant Treatment Period Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months Time to clinical response was defined as the time from the date of first dose received to the date of assessment of clinical response. Time to Clinical response was determined by Kaplan-Meier estimates. Tumor assessments were made based on the RECIST criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: CR: if measurement of '0' is noted at a given cycle as compared to baseline measurement which is \>0 at screening or cycle 1 day 1; PR: if measurement is at least a 30% decreased compared to baseline levels . (Reference= baseline size or sum of sizes). Clinical Responders are participants who have achieved CR or PR during the Neo-adjuvant treatment.
Percentage of Participants With Progressive Disease During Neo-Adjuvant Treatment Period Baseline up to Cycle 4 (assessed at Baseline, Day 1 of Cycles 1-4 Pre-Surgery) Up to approximately 24 months Tumor assessments were made based upon the Response Evaluation Criteria in Solid Tumors (RECIST) criteria - version 1.0. The clinical response at each cycle up to the last assessment prior to surgery was derived for: i) the primary breast lesion; (ii) across secondary breast lesions, (iii) across all breast lesions (iv) across axillary nodes (v) across supraclavicular nodes and (vi) across all nodes (vii) across all lesions (overall) using the following algorithm: PD: if lesion is at least a 20 % increased from measurements at baseline. Percentage of participants along with 95% Confidence Interval (CI) for one sample binomial using Pearson-Clopper method were reported. Missing investigator assessments were considered as no progressive disease.
Percentage of Participants Achieving Breast Conserving Surgery For Whom Mastectomy Was Planned Surgery (Within 2 weeks after Cycle 4) Up to approximately 24 months Breast Conserving Surgery (BCS) was defined as quadrantectomy, lumpectomy, no surgery, sentinel node biopsy, axillary surgical resection or other method of avoiding mastectomy.
Percentage of Participants Who Were Progression Free and Disease Free Randomization up to a maximum of 329 weeks Disease-free survival (DFS) was defined as the time from first date of no disease to first documentation of PD or death. Participants without progression after surgery were considered Disease Free. Any evidence of contralateral disease in-situ was not considered as PD. Participants who were withdrawn from the study without documented progression and for whom evaluations were made, were censored at date of last assessment when participant was known to be disease-free. Progression-free survival (PFS) was defined as time from date of randomization to first documentation of PD or death. Any evidence of contralateral disease in-situ was not considered as PD. Participants who were withdrawn from study without documented progression and for whom evaluations were made, were censored at date of last assessment when the participant was known to be free from progressive disease. Participants without post baseline assessments but known to be alive were censored at the time of randomization.
Progression Free and Disease Free Survival Randomization up to a maximum of 329 weeks DFS was defined as the time from the first date of no disease (date of surgery) to the first documentation of PD or death. Participants without progression after surgery were considered Disease Free. Any evidence of contralateral disease in-situ was not considered as PD. PFS was defined as the time from the date of randomization to the first documentation of PD or death. Any evidence of contralateral disease in-situ was not considered as PD. DFS and PFS were determined using Kaplan-Meier estimates.
Trial Locations
- Locations (77)
Geelong Hospital; Andrew Love Cancer Centre
🇦🇺Geelong, Victoria, Australia
ARKE Estudios Clínicos S.A. de C.V.
🇲🇽Mexico City, Mexico
Meir Medical Center; Oncology
🇮🇱Kfar-Saba, Israel
Oddzial Chemioterapii Szpitala Klinicznego Nr 1 w Poznaniu
🇵🇱Poznan, Poland
FSBI "Scientific Research Institute of Oncology named after N.N.Petrov" Ministry of Health of RF
🇷🇺St Petersburg, Leningrad, Russian Federation
SBI for HPE "Ryazan State Medical University n.a. I.P. Pavlov" of MoH of RF
🇷🇺Ryazan, Russian Federation
SBI of Healthcare Samara Regional Clinical Oncology Dispensary
🇷🇺Samara, Russian Federation
SI of Healthcare Kazan Oncology Dispensary
🇷🇺Kazan, Russian Federation
State Institution Of Healthcare Republican Oncology Dispensary
🇷🇺Petrozavodsk, Russian Federation
NSI of Healthcare Central Clinical Hospital #2 n.a. N.A.Semashko of the Russian Railways
🇷🇺Moscow, Russian Federation
Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
🇪🇸Sabadell, Barcelona, Spain
National Taiwan Uni Hospital; Dept of Oncology
🇨🇳Taipei, Taiwan
Chulalongkorn Hospital; Medical Oncology
🇹🇭Bangkok, Thailand
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
🇹🇭Bangkok, Thailand
Mount Medical Center
🇦🇺Perth, Western Australia, Australia
Hospital de Caridade de Ijui; Oncologia
🇧🇷Ijui, RS, Brazil
Ospedale San Raffaele, Servizio di Oncologia e Chemioterapia
🇮🇹Milano, Lombardia, Italy
Ospedale Di Vicenza; Nefrologia, Oncologia Medica
🇮🇹Vicenza, Veneto, Italy
Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology
🇰🇷Seoul, Korea, Republic of
Ospedale Calvi di Noale; U.O. Complessa di Oncologia ed Ematologia Oncologica
🇮🇹Mirano, Veneto, Italy
Samsung Medical Centre; Division of Hematology/Oncology
🇰🇷Seoul, Korea, Republic of
COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej
🇵🇱Lublin, Poland
Olsztyński Ośrodek Onkologiczny Kopernik sp. z o.o.
🇵🇱Olsztyn, Poland
Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii
🇵🇱Warszawa, Poland
Central Hospital of Military School of Medicine; Oncology
🇵🇱Warszawa, Poland
Russian Oncology Research Center n.a. N.N. Blokhin Dpt of Clinical Pharmacology and Chemotherapy
🇷🇺Moscow, Russian Federation
State Budget Institution of Healthcare of Stavropol region Pyatigorsk Oncology Dispensary
🇷🇺Pyatigorsk, Russian Federation
SI of HealthCare Oncologic Dispensary #2 of department of healthcare of Krasnodar region
🇷🇺Soshi, Russian Federation
SBI of Healthcare Leningrad Regional Oncology Dispensary
🇷🇺St Petersburg, Russian Federation
Ulyanovsk Regional Oncology Dispensary; Chemotherapy
🇷🇺Ulyanovsk, Russian Federation
Hospital de Cruces; Servicio de Oncologia
🇪🇸Barakaldo, Vizcaya, Spain
Hospital Universitario Reina Sofia; Servicio de Oncologia
🇪🇸Cordoba, Spain
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Ramon y Cajal; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario La Paz; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario Miguel Servet; Servicio Oncologia
🇪🇸Zaragoza, Spain
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
🇪🇸Valencia, Spain
Kantonsspital Baden; Frauenklinik
🇨🇭Baden, Switzerland
Akademiska sjukhuset, Onkologkliniken
🇸🇪Uppsala, Sweden
Brustzentrum
🇨🇭Zürich, Switzerland
VETERANS GENERAL HOSPITAL; Department of General Surgery
🇨🇳Taipei, Taiwan
Prince of Songkla Uni ; Unit of Medical Oncology
🇹🇭Songkhla, Thailand
Dokuz Eylul Uni Medical Faculty; Oncology Dept
🇹🇷Izmir, Turkey
Walsgrave Hospital; Dept of Oncology
🇬🇧Coventry, United Kingdom
Hacettepe Uni Medical Faculty Hospital; Oncology Dept
🇹🇷Sıhhiye, ANKARA, Turkey
Christie Hospital; Breast Cancer Research Office
🇬🇧Manchester, United Kingdom
Az. Osp. S. Orsola Malpighi; Istituto Di Oncologia Seragnoli
🇮🇹Bologna, Emilia-Romagna, Italy
Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia
🇮🇹Udine, Friuli-Venezia Giulia, Italy
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1
🇮🇹Milano, Lombardia, Italy
Karolinska Hospital; Oncology - Radiumhemmet
🇸🇪Stockholm, Sweden
Hospital Nossa Senhora da Conceicao
🇧🇷Porto Alegre, RS, Brazil
Hospital Amaral Carvalho
🇧🇷Jau, SP, Brazil
Kaiser Franz Josef Spital; Iii. Medizinische Abt. Mit Onkologie
🇦🇹Vienna, Austria
Hadassah Ein Karem Hospital; Oncology Dept
🇮🇱Jerusalem, Israel
Cancer Centre of Southeastern Ontario; Kingston General Hospital
🇨🇦Kingston, Ontario, Canada
CHU de Québec - Hôpital du Saint-Sacrement / ONCOLOGY
🇨🇦Quebec, Canada
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I
🇦🇹Wien, Austria
Moncton Hospital
🇨🇦Moncton, New Brunswick, Canada
Instituto de Oncologia de Sorocaba - CEPOS
🇧🇷Sorocaba, SP, Brazil
McGill University; Montreal General Hosptial; Oncology
🇨🇦Montreal, Quebec, Canada
University Health Network; Princess Margaret Hospital; Medical Oncology Dept
🇨🇦Toronto, Ontario, Canada
Clinica de Neoplasias Litoral
🇧🇷Itajai, SC, Brazil
Hospital Perola Byington
🇧🇷Sao Paulo, SP, Brazil
Inst. Brasileiro de Controle Ao Cancer; Oncologia Clinica / Quimioterapia
🇧🇷Sao Paulo, SP, Brazil
Instituto do Cancer Arnaldo Vieira de Carvalho - ICAVC; Pesquisa Clinica
🇧🇷Sao Paulo, SP, Brazil
Sourasky / Ichilov Hospital; Dept. of Oncology
🇮🇱Tel Aviv, Israel
ASST OVEST MILANESE; Oncologia Medica
🇮🇹Legnano, Lombardia, Italy
Polo Ospedaliero Santorso
🇮🇹Santorso, Veneto, Italy
NZOZ Centrum Medyczne HCP Sp. z o.o.
🇵🇱Poznan, Poland
Hospital Miguel Hidalgo
🇲🇽Aguascalientes, Mexico
Issstep Puebla, ; Oncology
🇲🇽Puebla, Mexico
Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica
🇵🇪Arequipa, Peru
Hospital Nacional Edgardo Rebagliati Martins; Oncologia
🇵🇪Lima, Peru
Samodzielny Publiczny Kliniczny Nr 1 W Lublinie; Klinika Chirurgii Onkologicznej
🇵🇱Lublin, Poland
Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology
🇨🇳Taipei, Taiwan
Faculdade de Medicina do ABC - FMABC; Oncologia e Hematologia
🇧🇷Santo Andre, SP, Brazil
Ospedale Regionale Di Parma; Divisione Di Oncologia Medica
🇮🇹Parma, Emilia-Romagna, Italy